

# **Incentives for development of ATMPs**

CAT Stakeholders Workshop EMA - London 12 January 2012





#### **Incentives**

- Incentives specific for ATMPs
  - Regulation EC No 1394/2007
- Other incentives
  - SMEs
  - Orphan medicines



### **Incentives: regulatory procedures**

- ► ATMP classification: To define Borderline e.g. with medical device, transplant, cosmetics.
- ► ATMP Certification: Assessment of early quality and non-clinical data. Incentive only for SMEs.
- ► MAA: evaluation by CAT: committee with specific expertise
- Scientific advice: can be given on ANY scientific question (Quality, non-clinical and clinical). At any time point of the development. CAT contributes to all ATMP SA/PA



#### **Financial incentives**

- ► Scientific Advice: 90% fee reduction for SMEs, 65% for others
- ► ATMP classification: free, 60 days
- ▶ ATMP Certification: from 3810 to 5720 Euros
- ► 50% fee reduction for **MAA** (until 2011/2012) for hospitals and SMEs for products of particular public health interest in the Community
- ► **Orphan drugs**: designation free, SA free, 50%-100% reduction on MAA
- ▶ Products legally on the market: MAA free until 2011-2012



#### **Incentives: dedicated expertise**

- Dedicated Committee
- Dedicated EMA Secretariat
  - Use the scientific administrators at EMA
  - Teleconferences
  - Procedural advices
  - Links to other EMA sections (paediatrics, SME office, Regulatory)
- Scientific advice
  - Pre-submission meetings recommended for ATMPs
  - Come for clarifications and follow-up advice as often as needed




### **Incentives: Support to Applicants**

- Innovation Task Force (ITF) Briefing Meetings <u>Link</u> to ITF webpage
- ► SME Office Link to SME office webpages
- Orphan designation Link to ODD webpage

## Challenges with ATMPs: how caneuropean Medicines AGENCY

## EMA/CAT help?

ITF Briefing meetings





### Thank you for your attention!

More info? Link to ATMP webpage
General e-mail for queries:
AdvancedTherapies@ema.europa.eu